BRPI0714908B8 - derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende - Google Patents
derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreendeInfo
- Publication number
- BRPI0714908B8 BRPI0714908B8 BRPI0714908A BRPI0714908A BRPI0714908B8 BR PI0714908 B8 BRPI0714908 B8 BR PI0714908B8 BR PI0714908 A BRPI0714908 A BR PI0714908A BR PI0714908 A BRPI0714908 A BR PI0714908A BR PI0714908 B8 BRPI0714908 B8 BR PI0714908B8
- Authority
- BR
- Brazil
- Prior art keywords
- pi3k inhibitor
- pharmaceutical composition
- proliferative disease
- pyrimidine derivatives
- agent
- Prior art date
Links
- 239000012828 PI3K inhibitor Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
derivado de pirimidina como inibidor de pi3k e uso do mesmo. é fornecido um fármaco que é útil como preventivo ou terapêutico para câncer tendo como resultado efeitos inibidores de pi3k superiores, bem como estabilidade superior no corpo e solubilidade em água. um composto, ou sal farmaceuticamente aceitável deste, representado pela fórmula (i): (i) [em que, x representa, por exemplo, uma ligação simples; y representa, por exemplo, uma ligação simples (contanto que x e y não sejam simultaneamente ligações simples); z representa por exemplo, um átomo de hidrogênio etc.; m representa um número inteiro de 1 ou 2; e r1 representa um substituinte cíclico].
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006216108 | 2006-08-08 | ||
| JP2006-216108 | 2006-08-08 | ||
| JP2007118631 | 2007-04-27 | ||
| JP2007-118631 | 2007-04-27 | ||
| PCT/JP2007/065396 WO2008018426A1 (en) | 2006-08-08 | 2007-08-07 | Pyrimidine derivative as pi3k inhibitor and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0714908A2 BRPI0714908A2 (pt) | 2013-05-28 |
| BRPI0714908B1 BRPI0714908B1 (pt) | 2020-10-13 |
| BRPI0714908B8 true BRPI0714908B8 (pt) | 2021-05-25 |
Family
ID=39032956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0714908A BRPI0714908B8 (pt) | 2006-08-08 | 2007-08-07 | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8022205B2 (pt) |
| EP (1) | EP2050749B1 (pt) |
| JP (1) | JP4450857B2 (pt) |
| KR (1) | KR101435692B1 (pt) |
| AR (1) | AR062292A1 (pt) |
| AU (1) | AU2007282535B9 (pt) |
| BR (1) | BRPI0714908B8 (pt) |
| CA (1) | CA2659604C (pt) |
| CL (1) | CL2007002316A1 (pt) |
| CY (1) | CY1119882T1 (pt) |
| DK (1) | DK2050749T3 (pt) |
| ES (1) | ES2657635T3 (pt) |
| HU (1) | HUE035116T2 (pt) |
| IL (1) | IL196601A (pt) |
| LT (1) | LT2050749T (pt) |
| MX (1) | MX2009001451A (pt) |
| MY (1) | MY145385A (pt) |
| NO (1) | NO342978B1 (pt) |
| NZ (1) | NZ575274A (pt) |
| PE (1) | PE20080527A1 (pt) |
| PL (1) | PL2050749T3 (pt) |
| PT (1) | PT2050749T (pt) |
| RU (1) | RU2448109C2 (pt) |
| SI (1) | SI2050749T1 (pt) |
| TW (1) | TWI394758B (pt) |
| WO (1) | WO2008018426A1 (pt) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5498796B2 (ja) * | 2006-12-21 | 2014-05-21 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ピラゾロ−キナゾリン誘導体、これらの調製方法及びキナーゼ阻害剤としてのこれらの使用 |
| CL2009000241A1 (es) * | 2008-02-07 | 2010-09-03 | Chugai Pharmaceutical Co Ltd | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| LT3289876T (lt) * | 2008-06-16 | 2022-11-10 | University Of Tennessee Research Foundation | Junginiai, skirti vėžio gydymui |
| JP2011527342A (ja) * | 2008-07-07 | 2011-10-27 | エックスカバリー ホールディング カンパニー エルエルシー | Ｐｉ３ｋアイソフォーム選択的阻害剤 |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010056320A2 (en) * | 2008-11-11 | 2010-05-20 | Tyrogenex, Inc. | Pi3k/mtor kinase inhibitors |
| ES2462715T3 (es) * | 2008-12-19 | 2014-05-26 | Genentech, Inc. | Compuestos y métodos de uso |
| US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| WO2010114494A1 (en) * | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders |
| JP5721706B2 (ja) | 2009-06-17 | 2015-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルス複製の阻害剤 |
| DK2448938T5 (en) | 2009-06-29 | 2015-10-05 | Incyte Corp | Pyrimidinones AS PI3K inhibitors |
| ES2706185T3 (es) | 2009-07-07 | 2019-03-27 | Mei Pharma Inc | Pirimidinil y 1,3,5-triazinil bencimidazoles y sus usos en la terapia contra el cáncer |
| TWI499592B (zh) * | 2009-09-09 | 2015-09-11 | Avila Therapeutics Inc | Ｐｉ３激酶抑制劑及其用途 |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| KR20130113950A (ko) * | 2010-05-19 | 2013-10-16 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | Ｍｔｏｒ 선택적 키나아제 억제제 |
| AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
| KR20130116358A (ko) * | 2011-02-09 | 2013-10-23 | 에프. 호프만-라 로슈 아게 | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 |
| ES2608967T3 (es) | 2011-03-28 | 2017-04-17 | Mei Pharma, Inc. | (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas |
| CN106432311A (zh) * | 2011-07-05 | 2017-02-22 | 沃泰克斯药物股份有限公司 | 生产氮杂吲哚类的方法和中间体 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| HRP20170285T1 (hr) | 2011-09-02 | 2017-04-21 | Incyte Holdings Corporation | Heterociklilamini kao inhibitori pi3k |
| US20130123255A1 (en) * | 2011-11-10 | 2013-05-16 | Chugai Seiyaku Kabushiki Kaisha | Combination of a pi3k inhibitor and a mek inhibitor |
| EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| CN104349779A (zh) | 2012-05-16 | 2015-02-11 | 诺华股份有限公司 | Pi-3激酶抑制剂的剂量方案 |
| CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| HUE036188T2 (hu) * | 2012-07-02 | 2018-06-28 | Taiho Pharmaceutical Co Ltd | Egy imidazooxazin vegyületet tartalmazó tumorellenes hatás potenciátor |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| MX386085B (es) * | 2012-11-01 | 2025-03-18 | Infinity Pharmaceuticals Inc | Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa |
| CN103588792B (zh) | 2013-03-04 | 2016-03-23 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| MX381304B (es) * | 2013-10-16 | 2025-03-12 | Shanghai Yingli Pharm Co Ltd | Compuesto heterocíclico fusionado, método de preparación del mismo, composición farmacéutica, y usos del mismo. |
| PT3068782T (pt) | 2013-11-13 | 2018-10-08 | Vertex Pharma | Métodos de preparação de inibidores da replicação de vírus da gripe |
| PT3126528T (pt) | 2014-04-04 | 2021-09-09 | Crown Bioscience Inc Taicang | Métodos para determinar a responsividade a inibidores de mek/erk |
| WO2015155624A1 (en) * | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| HK1245794A1 (zh) | 2015-02-27 | 2018-08-31 | 大鹏药品工业株式会社 | 咪唑并恶嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
| MX373232B (es) | 2015-02-27 | 2020-05-08 | Incyte Holdings Corp | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación. |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| PT3458067T (pt) | 2016-05-18 | 2021-04-07 | Univ Basel | Tratamento de distúrbios neurológicos |
| EP3481829B1 (en) | 2016-07-08 | 2021-04-07 | H. Hoffnabb-La Roche Ag | Fused pyrimidine derivatives |
| EP3484884B1 (en) | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| IT201600092469A1 (it) * | 2016-09-14 | 2018-03-14 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Blonanserina |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| EP3523304B1 (en) | 2016-10-04 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bicyclic heteroaryl derivatives |
| JP7309614B2 (ja) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | 組み合わせ療法 |
| KR20240097982A (ko) | 2017-05-23 | 2024-06-27 | 메이 파마, 아이엔씨. | 병용 요법 |
| MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
| JP7335242B2 (ja) | 2017-11-27 | 2023-08-29 | エフ． ホフマン－ラ ロシュ アーゲー | ピリミジン誘導体 |
| MX2020012826A (es) | 2018-06-01 | 2021-03-09 | Incyte Corp | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |
| CN113795490A (zh) | 2019-05-13 | 2021-12-14 | 诺华股份有限公司 | N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症 |
| WO2021247862A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Bicyclic heteroarenes and methods of their use |
| TW202220661A (zh) | 2020-08-07 | 2022-06-01 | 德商柏林化學股份公司 | 包含pi3k抑制劑之經改良醫藥調配物 |
| CA3215002A1 (en) | 2021-04-09 | 2022-10-13 | Christian Gege | Deuterated dhodh inhibitors |
| EP4444317A4 (en) * | 2021-12-08 | 2025-12-17 | Kineta Inc | BICYCLE HETEROARENS AND METHODS FOR THEIR USE |
| AU2022407039A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Pyrimidines and methods of their use |
| WO2024023766A1 (en) | 2022-07-28 | 2024-02-01 | Berlin-Chemie Ag | P13k inhibitor combination therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08325268A (ja) | 1986-02-24 | 1996-12-10 | Mitsui Petrochem Ind Ltd | ピロロ〔３，４−ｄ〕ピリミジン誘導体 |
| DE3752141T2 (de) * | 1986-02-24 | 1998-03-26 | Mitsui Petrochemical Ind | Mittel zur behandlung von neuropathie |
| DK0495982T3 (da) * | 1989-10-11 | 1996-07-01 | Teijin Ltd | Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel |
| TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| BR0114829A (pt) | 2000-10-23 | 2003-09-23 | Smithkline Beecham Corp | Novos compostos |
| WO2004043367A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
| US7423148B2 (en) * | 2002-11-21 | 2008-09-09 | Chiron Corporation | Small molecule PI 3-kinase inhibitors and methods of their use |
| JP2006525261A (ja) * | 2003-05-05 | 2006-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｒｆ活性を有する縮合ピリミジン誘導体 |
-
2007
- 2007-08-07 CA CA2659604A patent/CA2659604C/en active Active
- 2007-08-07 LT LTEP07792065.0T patent/LT2050749T/lt unknown
- 2007-08-07 EP EP07792065.0A patent/EP2050749B1/en active Active
- 2007-08-07 MX MX2009001451A patent/MX2009001451A/es active IP Right Grant
- 2007-08-07 BR BRPI0714908A patent/BRPI0714908B8/pt active IP Right Grant
- 2007-08-07 MY MYPI20090459A patent/MY145385A/en unknown
- 2007-08-07 SI SI200731994T patent/SI2050749T1/en unknown
- 2007-08-07 ES ES07792065T patent/ES2657635T3/es active Active
- 2007-08-07 WO PCT/JP2007/065396 patent/WO2008018426A1/ja not_active Ceased
- 2007-08-07 JP JP2008528817A patent/JP4450857B2/ja active Active
- 2007-08-07 KR KR1020097002650A patent/KR101435692B1/ko active Active
- 2007-08-07 HU HUE07792065A patent/HUE035116T2/hu unknown
- 2007-08-07 NZ NZ575274A patent/NZ575274A/en unknown
- 2007-08-07 US US12/376,039 patent/US8022205B2/en active Active
- 2007-08-07 PL PL07792065T patent/PL2050749T3/pl unknown
- 2007-08-07 PT PT77920650T patent/PT2050749T/pt unknown
- 2007-08-07 AU AU2007282535A patent/AU2007282535B9/en active Active
- 2007-08-07 DK DK07792065.0T patent/DK2050749T3/en active
- 2007-08-07 RU RU2009108328/04A patent/RU2448109C2/ru active
- 2007-08-08 PE PE2007001059A patent/PE20080527A1/es active IP Right Grant
- 2007-08-08 CL CL200702316A patent/CL2007002316A1/es unknown
- 2007-08-08 TW TW096129165A patent/TWI394758B/zh active
- 2007-08-08 AR ARP070103510A patent/AR062292A1/es active IP Right Grant
-
2008
- 2008-10-28 NO NO20084533A patent/NO342978B1/no unknown
-
2009
- 2009-01-20 IL IL196601A patent/IL196601A/en active IP Right Grant
-
2017
- 2017-12-28 CY CY20171101353T patent/CY1119882T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0714908B8 (pt) | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
| NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
| BRPI0511504A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides | |
| BRPI0515488A (pt) | derivados de heterocìclicos e seu uso como agentes terapêuticos | |
| NO20090443L (no) | 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| DE60140814D1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
| EA201070588A1 (ru) | Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| UA97351C2 (ru) | Производная кумарина, имеющая противоопухолевую активность | |
| NO20053775L (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
| BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
| BRPI0513184A (pt) | derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia | |
| RU2011138962A (ru) | Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1 | |
| MX2009008386A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer. | |
| AR043662A1 (es) | Derivados de guanidina | |
| WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| MX2008016358A (es) | Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |